Dia-Präsentation von Merck Gesellschaft mbH. Micardis(R) - Micardis Plus(R) - Effekte bei Zielorganschädigung (16 Abbildungen) Übersicht
| ||||||||||||||||||
Abbildung 13: Telmisartan - LVH This clinical study assessed the effect of 12 months’ treatment with telmisartan 40–80 mg on LVMI in 90 patients with hypertension and echocardiographic evidence of mild-to-moderate LVH.1 There was a significant improvement in diastolic filling: the early to atrial filling ratio increased from 0.59 ± 0.2 at baseline to 0.88 ± 0.2 at study end (P<0.05). 1. Mattioli AV, Zennaro M, Bonatti S, Bonetti L, Mattioli G. Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. Int J Cardiol 2004; 97: 383–388. |
![]()
Abbildung 13: Telmisartan - LVH
This clinical study assessed the effect of 12 months’ treatment with telmisartan 40–80 mg on LVMI in 90 patients with hypertension and echocardiographic evidence of mild-to-moderate LVH.1 There was a significant improvement in diastolic filling: the early to atrial filling ratio increased from 0.59 ± 0.2 at baseline to 0.88 ± 0.2 at study end (P<0.05). 1. Mattioli AV, Zennaro M, Bonatti S, Bonetti L, Mattioli G. Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. Int J Cardiol 2004; 97: 383–388. |